Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

BIOLOGICAL(2)
EBV-specific T cells (EBV-CTLs)
1 trial
phase_2
atara-biotherapeutics
Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
1 trial
phase_1_2
atara-biotherapeutics
2 unique interventions1 categories

Analytics

Trial Phases

Phase 11
Phase 22

Trial Status

Completed2

Role Distribution

Other Roles2

Activity Timeline

Clinical Trials (2)

NCT01498484Phase 2Completed
Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
EBV-associated MalignanciesEBV-induced LymphomasTransplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
StudydirectorStart date: 2011-12-01
NCT00002663Phase 1/2Completed
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
EBV-associated MalignanciesEBV-induced LymphomasTransplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
StudydirectorStart date: 1995-03-01

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

1 similar investigators found

Susan Prockop, MD

Memorial Sloan Kettering Cancer Center

Related
7 trials

Shared therapeutic areas:

EBV-associated Malignancies

Worked with same sponsors:

Atara BiotherapeuticsMemorial Sloan Kettering Cancer Center+1 more
Similarity Score8%

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT01498484Phase 2StudyDirector

Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

EBV-associated MalignanciesEBV-induced LymphomasTransplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
Completed
NCT00002663Phase 1/2StudyDirector

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

EBV-associated MalignanciesEBV-induced LymphomasTransplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
Completed

All 2 trials loaded